Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6–11 Years: Actual Observations and Clinical Perspectives.

Simple item page
dc.contributor.authorPérez Ruiz, Margarita
dc.contributor.authorBos, Mats te
dc.contributor.authorFernández García, Patricia
dc.contributor.authorManuel, Cristina de
dc.contributor.authorMorales Tirado, Ana
dc.contributor.authorLópez Neyra, Alejandro
dc.contributor.authorRuiz de Valbuena, Marta
dc.contributor.authorRubio Alonso, Margarita
dc.contributor.authorSanz Santiago, Verónica
dc.date.accessioned2025-10-20T08:04:53Z
dc.date.available2025-10-20T08:04:53Z
dc.date.issued2025
dc.description.abstractCystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life studies. This study aimed to assess the impact of ETI on aerobic capacity in children with CF aged 6–11 years under real-life conditions and to evaluate whether prior CFTR modulator treatment affects these outcomes.
dc.description.filiationUEM
dc.description.impact9.2 Q1 JCR 2024spa
dc.description.impact0.466 Q3 SJR 2024spa
dc.description.impactNo data IDR 2023spa
dc.description.sponsorshipSn financiación
dc.identifier.citationPérez-Ruiz, M., Te Bos, M., Fernández-García, P., Manuel, C. D., Morales-Tirado, A., López-Neyra, A., Valbuena, M. R. D., Rubio, M., & Sanz-Santiago, V. (2025). Evaluation of the impact of elexacaftor/tezacaftor/ivacaftor on aerobic capacity in children with cystic fibrosis aged 6–11 years: Actual observations and clinical perspectives. Archivos de Bronconeumología, S0300289625000717. https://doi.org/10.1016/j.arbres.2025.02.010
dc.identifier.doi10.1016/j.arbres.2025.02.010
dc.identifier.issn0300-2896
dc.identifier.urihttps://hdl.handle.net/11268/16408
dc.language.isoeng
dc.peerreviewedSi
dc.relation.publisherversionhttp://doi.org/10.1016/j.arbres.2025.02.010
dc.rightsSin licencia Creative Commonseng
dc.rights.accessRightsopen access
dc.subject.otherNiño
dc.subject.otherFibrosis Quística
dc.subject.otherCalidad de vida
dc.subject.sdgGoal 3: Ensure healthy lives and promote well-being for all at all ages
dc.subject.unescoSalud
dc.subject.unescoAparato respiratorio
dc.subject.unescoSalud materno-infantil
dc.titleEvaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6–11 Years: Actual Observations and Clinical Perspectives.
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationa5c08444-aa82-4924-a71e-de56086bcd7c
relation.isAuthorOfPublication0413b5c5-4ebf-4116-b5d7-829f891a6e9c
relation.isAuthorOfPublication.latestForDiscoverya5c08444-aa82-4924-a71e-de56086bcd7c

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Evaluation of the Impact of Elexacaftor_Tezacaftor_Ivacaftor on Aerobic Capacity_2025.docx
Size:
13.93 KB
Format:
Microsoft Word XML
Download

Collections

Área de Ciencias de la Salud